Learning from the COVID-19 Pandemic and AKI Evolution for Extracorporeal and Adsorption Techniques in Kidney Replacement Therapy

Increased mortality has been observed in patients who develop acute kidney injury (AKI) the setting of coronavirus disease 2019 (COVID-19), which led to approval extracorporeal support by FDA. We analyzed existing literature compare efficacy and therapeutic benefits various modalities for oXiris membranes CytoSorb cartridge high-flow continuous replacement therapy (HFCKRT). AKI due COVID-19 is mediated a state systemic inflammation (cytokine storm syndrome), leading multiple organ dysfunction. Although there no consensus on protocol providing therapy, clinically oriented studies have shown capacities filters effectively filter out pro-inflammatory components, improved clinical outcomes critically ill patients. In this review, we study development cytokine syndrome, important evidence regarding roles adsorption techniques setting, influenced FDA recommendations membranes.